Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Warren P Mason

Showing results (91-100 of 116) with videos related to

Pageof 12
Sort By:
Neuro-Oncology|January 22, 2015
Phase II study of PX-866 in recurrent glioblastomaMarshall W Pitz, Elizabeth A Eisenhauer, Mary V MacNeil, et al.
The Lancet. Neurology|January 28, 2014
Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodiesMar Petit-Pedrol, Thaís Armangue, Xiaoyu Peng, et al.
The New England Journal of Medicine|March 11, 2005
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastomaRoger Stupp, Warren P Mason, Martin J van den Bent, et al.
Acta Neuropathologica|January 18, 2012
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trialMonika E Hegi, Robert-Charles Janzer, Wanyu L Lambiv, et al.
The Lancet. Oncology|October 1, 2016
Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup studyJaap C Reijneveld, Martin J B Taphoorn, Corneel Coens, et al.
The Lancet. Oncology|March 10, 2009
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialRoger Stupp, Monika E Hegi, Warren P Mason, et al.
Neuro-Oncology|April 4, 2017
Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOGDeborah T Blumenthal, Thierry Gorlia, Mark R Gilbert, et al.
The New England Journal of Medicine|March 16, 2017
Short-Course Radiation plus Temozolomide in Elderly Patients with GlioblastomaJames R Perry, Normand Laperriere, Christopher J O'Callaghan, et al.
The Lancet. Oncology|November 28, 2021
Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trialPatrick Y Wen, Alexander Stein, Martin van den Bent, et al.
The New England Journal of Medicine|June 5, 2023
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaIngo K Mellinghoff, Martin J van den Bent, Deborah T Blumenthal, et al.
Pageof 12

Showing results (91-100 of 116) with videos related to

Sort By:
Pageof 12
Neuro-Oncology|January 22, 2015
Phase II study of PX-866 in recurrent glioblastomaMarshall W Pitz, Elizabeth A Eisenhauer, Mary V MacNeil, et al.
The Lancet. Neurology|January 28, 2014
Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodiesMar Petit-Pedrol, Thaís Armangue, Xiaoyu Peng, et al.
The New England Journal of Medicine|March 11, 2005
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastomaRoger Stupp, Warren P Mason, Martin J van den Bent, et al.
Acta Neuropathologica|January 18, 2012
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trialMonika E Hegi, Robert-Charles Janzer, Wanyu L Lambiv, et al.
The Lancet. Oncology|October 1, 2016
Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup studyJaap C Reijneveld, Martin J B Taphoorn, Corneel Coens, et al.
The Lancet. Oncology|March 10, 2009
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialRoger Stupp, Monika E Hegi, Warren P Mason, et al.
Neuro-Oncology|April 4, 2017
Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOGDeborah T Blumenthal, Thierry Gorlia, Mark R Gilbert, et al.
The New England Journal of Medicine|March 16, 2017
Short-Course Radiation plus Temozolomide in Elderly Patients with GlioblastomaJames R Perry, Normand Laperriere, Christopher J O'Callaghan, et al.
The Lancet. Oncology|November 28, 2021
Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trialPatrick Y Wen, Alexander Stein, Martin van den Bent, et al.
The New England Journal of Medicine|June 5, 2023
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaIngo K Mellinghoff, Martin J van den Bent, Deborah T Blumenthal, et al.
Pageof 12